About
Pepper Bio, founded in 2018 in Massachusetts, USA, analyzes multi-layered biological data—including DNA, RNA, proteomic, and phosphoproteomic data—to discover novel drug candidates.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Company· 12
Investor· 7
Founders / team· 1
Funding history
- 2023-12Seed$7M
Investors · Merck Global Health Innovation Fund, Merck, Tensility Ventures, Mana Ventures, VSC Ventures, NFX, Silverton PartnersSource · SVTR Weekly #030
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Pepper Bio
Analyzes multi-layer biological data (including DNA, RNA, proteomic and phosphoproteomic data) to discover new drugs
Seed · $7M · 2023-12
$7M
United States
BusinessLatest roundTotal raisedDate- 10x Science
AI analysis of experimental data to identify and characterize proteins for drug development
Seed · $5M · 2026-04
$5M - Escalante
Drug discovery and diagnostics platform combining AI with single-molecule proteomics
$7M
$7M - RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M
China
BusinessLatest roundTotal raisedDate- Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M - Syneron Bio
AI-driven synthetic peptide drug developer focused on a pipeline of next-generation synthetic peptide and protein drugs
Series B · $280M · 2026-04
$280M - NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)
Series B · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- OutSee
AI analysis of individual genomes to predict disease biology and help drug developers find new targets
Seed · $2M · 2025-06
$2M - Bio Protocol
Funds and accelerates drug discovery through decentralized research agents
Seed · $7M · 2025-09
$7M - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M
Other / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 19 at a nearby stage · 36 in United States
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 26 at a nearby stage · 31 in United States
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage · 22 in United States
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 20 in United States
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 15 in United States
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 5 at a nearby stage · 15 in United States
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.